

PRODUCT MONOGRAPH

IMMUNINE VH

(Factor IX Concentrate (Human), Vapor Heated, IMMUNO)

Freeze-dried powder with diluent for intravenous injection

480 -720 IU¹/5 mL,

Pharmacopeial

Hemostatic

Shire Pharma Canada ULC
22 Adelaide Street West, Suite 3800
Toronto Ontario M5H 4E3

Submission Control No: 214296

Date of Approval: April 23, 2018

¹ IU based on the 1st International Standard for Human Blood Coagulation Factors II, IX, and X in Concentrates, Code 84/681

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION 3
SUMMARY PRODUCT INFORMATION..... 3
DESCRIPTION 3
INDICATIONS AND CLINICAL USE..... 3
CONTRAINDICATIONS 4
WARNINGS AND PRECAUTIONS..... 4
ADVERSE REACTIONS..... 8
DRUG INTERACTIONS10
DOSAGE AND ADMINISTRATION10
OVERDOSAGE15
ACTION AND CLINICAL PHARMACOLOGY.....15
STORAGE AND STABILITY16
SPECIAL HANDLING INSTRUCTIONS.....16
DOSAGE FORMS, COMPOSITION AND PACKAGING.....16

PART II: SCIENTIFIC INFORMATION..... 17
PHARMACEUTICAL INFORMATION18
DETAILED PHARMACOLOGY20
TOXICOLOGY21
REFERENCES22

PART III: CONSUMER INFORMATION..... 24

IMMUNINE VH

(Factor IX Concentrate (Human), Vapor Heated, IMMUNO)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous	Powder and solvent for solution for injection or infusion. White or pale yellow lyophilized powder or friable solid. 480 -720 IU ¹ /5 mL,	Factor II, VII and X (<0.02 IU / 1 IU factor IX), Tween 80, Sodium Chloride and Sodium Citrate. <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

DESCRIPTION

IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, is a purified, sterile, freeze-dried concentrate of human blood coagulation factor IX. IMMUNINE VH is standardized in terms of factor IX content and each vial is labeled with the factor IX content indicated in international units (IU) (1, 2). One international unit of factor IX (based on the First International Standard for Factors II, IX and X in Coagulation Factor Concentrates Code 84/681) corresponds to the factor IX activity contained in 1 ml of fresh normal human plasma.

INDICATIONS AND CLINICAL USE

IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO is indicated for:

- Therapy and prophylaxis of bleeding episodes caused by congenital or acquired factor IX deficiency.

CONTRAINDICATIONS

IMMUNINE must not be used in the following situations if therapeutic alternatives to IMMUNINE are available:

- Hypersensitivity to any component of the product.
- Known allergy to heparin or history of heparin induced thrombocytopenia.
- Disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis. Following interruption of these processes by suitable means IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO should only be given for the management of life-threatening bleeding.

WARNINGS AND PRECAUTIONS

General

IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO should not be administered at a rate exceeding 2 mL/min.

IMMUNINE VH contains less than 0.1 IU heparin per ml. In case of surgical intervention in hemophilia B patients receiving replacement therapy with IMMUNINE VH, perioperative thrombosis prophylaxis with low-dose heparin is recommended in those situations where such a prophylaxis would normally be indicated in patients having no coagulation defect.

IMMUNINE VH contains not more than 5 µg TWEEN 80 per ml.

Viral safety

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as human immunodeficiency (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) and for the non-enveloped virus hepatitis A virus (HAV).

The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g., in hemolytic anemia).

Individuals who receive infusion of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly nonA, nonB hepatitis.

Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma derived factor IX concentrates.

Immune

Anaphylaxis/anaphylactoid and other severe hypersensitivity reactions have been reported with IMMUNINE. Patients and/or their caregivers should be informed of the early signs of hypersensitivity reactions. They should be advised to discontinue use of the product immediately and contact their physician if such symptoms occur. Minor reactions may be controlled by antihistamines, while the therapy of severe hypotensive reactions follows the current guideline of shock treatment.

As a plasma derived factor IX concentrate, the product contains other human proteins.

There have been reports in the literature showing an association between the occurrence of a factor IX inhibitor and allergic reactions, in particular in patients with a high risk gene mutation. Therefore, patients experiencing allergic reactions should be evaluated for the presence of an inhibitor.

Because of the risk of allergic reactions with factor IX concentrates, the initial administrations of factor IX should be performed under medical observation where proper immediate medical care for severe allergic/anaphylactic reactions could be provided, in particular in patients with high risk gene mutations or where the mutation is unknown.

In case of shock, the current medical standards for shock treatment should be observed.

Sensitivity/Resistance

Inhibitors

Patients with hemophilia B may develop neutralizing antibodies (inhibitors) to factor IX.

After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralizing antibodies (inhibitors) that should be quantified in

Bethesda Units (BU) using appropriate biological testing.

If such inhibitors occur, the condition will manifest itself as an insufficient clinical response.

If a patient develops an inhibitor, it is recommended that a specialized hemophilia center be contacted.

Patients with factor IX inhibitors are at an increased risk of severe hypersensitivity reactions or anaphylaxis with subsequent challenges with factor IX.

Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors.

Sodium Content

The calculated sodium content of the IMMUNINE 600 IU formulation is 20.4 mg per vial. The quantity of sodium in a high single dose in adults may exceed 250 mg for the 600 IU/5mL formulation. This is to be taken into consideration in patients on a low-sodium diet.

This following example is based on the assumption of a 70 kg patient, needing a 99% increase, and using the formula $70 \times 99 \times 1.1 = 7623$ Units needed.

In this example of 12.7 vials at 600 IU.

600 IU vials contain 20.4 mg sodium \approx 259.08 mg Na⁺

Hematologic

Since the use of factor IX complex concentrates has historically been associated with the development of thromboembolic complications, the risk being higher in low purity preparations, the use of factor IX-containing products may be potentially hazardous in patients with disseminated intravascular coagulation (DIC) and in patients with signs of fibrinolysis.

Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing, in particular when administering this product to patients with liver disease, to patients peri- and postoperatively, or to other patients at risk for thrombotic events or DIC.

In patients with DIC or those at risk for DIC or thromboembolic events, the benefit of treatment with IMMUNINE should be weighed against the risk of these complications.

In patients with a risk of thrombosis (e.g. patients with a history of severe liver disease,

thrombophilia, or a tentative or definite diagnosis of angina pectoris, coronary heart disease or myocardial infarction) the factor IX level should not be raised beyond 60% of normal. In addition, these patients - as well as patients receiving high doses of human blood coagulation factor IX concentrate for major surgery - should be monitored for the development of DIC and/or thrombosis (3).

Special Populations

Pregnant Women:

There is no adequate data from the use of IMMUNINE in pregnant or lactating women. Healthcare providers should balance the potential risks and only prescribe IMMUNINE if clearly needed.

The effects of IMMUNINE on fertility have not been established.

Nursing Women:

The safety of IMMUNINE for use in lactating women has not been established. Physicians should carefully consider the potential risks and benefits for each specific patient before prescribing IMMUNINE.

Pediatrics:

There is limited data available in children.

Geriatrics:

There is no data available to determine whether subjects aged 65 and over respond differently from younger subjects.

Monitoring and Laboratory Tests

During the course of treatment, appropriate determination of factor IX levels is advised to guide the dose to be administered and the frequency of repeated infusions. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma Factor IX activity) is indispensable. Individual patients may vary in their response to factor IX, achieving different levels of *in vivo* recovery and demonstrating different half-lives.

If bleeding does not resolve despite adequate treatment, clotting factor levels should be measured. Inhibitor testing should be performed if the level is unexpectedly low, as this may be an indication that factor IX inhibitor is present. Allergic reactions, including anaphylaxis is another indicator of inhibitor development and warrants inhibitor testing (see Warnings and Precautions).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

As with any infused plasma derivative, hypersensitivity reactions (e.g. fever, urticaria, nausea, vomiting, dyspnea, drop in blood pressure, shock) may occur rarely.

In rare cases, replacement therapy with human blood coagulation factor IX concentrates may lead to the formation of circulating antibodies which inhibit factor IX.

The possibility of thromboembolic complications cannot be entirely ruled out. This applies particularly to patients at risk for thrombosis and/or receiving high-dose therapy.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse drug reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The adverse reactions presented in this section have been identified from 5 prospective clinical trials (IMAG-036, IMAG-037, IMAG-092, IMAG-115, and IMAG-169) conducted with IMMUNINE (product with and without heparin) in 148 subjects administered 2807 infusions.

System Organ Class (SOC)	Adverse Reaction	Frequency	
		Category	Frequency Ratio (Percentage)
RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS	Throat irritation	Uncommon	3/2807 (0.11%)
	Oropharyngeal pain	Rare	1/2807 (0.04%)
	Cough (dry)	Rare	1/2807 (0.04%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	Rash	Uncommon	1/2807 (0.04%)
	Pruritus	Rare	1/2807 (0.04%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	Pyrexia	Rare	1/2807 (0.04%)

Legend: ADR frequency is based upon the following scale: Very Common ($\geq 1/10$); Common ($\geq 1/100 - < 1/10$), Uncommon ($\geq 1/1,000 - < 1/100$), Rare ($\geq 1/10,000 - < 1/1,000$), Very Rare ($< 1/10,000$)

Inhibitor development to factor IX has been reported (see Section on Post-Market Adverse Drug Reactions). In clinical trials with IMMUNINE, no factor IX inhibitors were identified in 41 patients having a total of 2079 exposure days to IMMUNINE in the clinical trials. No previously untreated patients were enrolled in IMMUNINE clinical trials.

Post-Market Adverse Drug Reactions

The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA (vers. 15.0) System Organ Class (SOC), then by Preferred Term in order of severity, where feasible.

Blood and Lymphatic System Disorders: Factor IX Inhibition

Immune System Disorders: Anaphylactic/Anaphylactoid Reaction, Serum Sickness (In The Presence Of Inhibitors), Hypersensitivity Reaction

Nervous System Disorders: Headache

Cardiac Disorders: Myocardial Infarction, Tachycardia

Vascular Disorders: Flushing

Respiratory, Thoracic, And Mediastinal Disorders: Dyspnea

Skin and Subcutaneous Tissue Disorders: Urticaria

General Disorders and Administration Site Conditions: Chills

Class Reactions

Disseminated intravascular coagulation, thromboembolic episodes (e.g., pulmonary embolism, venous thrombosis, arterial thrombosis, cerebral artery thrombosis)

Other manifestations of hypersensitivity or allergic reactions: anaphylactic shock, angioedema, chest tightness, hypotension, lethargy, nausea, vomiting, paresthesia, restlessness, wheezing.

Nephrotic syndrome (following attempted immune tolerance induction)

DRUG INTERACTIONS

Overview

No interactions of human coagulation factor IX products with other medicinal products are known.

As for any blood coagulation factor concentrate IMMUNINE VH Factor IX Concentrate (Human) Vapor Heated, IMMUNO, should not be mixed with other drugs. It is advisable to rinse a common venous access with isotonic saline prior to and after infusion of IMMUNINE VH.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Treatment should be initiated under the supervision of a physician experienced in the treatment of hemophilia.

The dosage and duration of treatment depend on the severity of factor IX deficiency, the location and extent of the bleeding, and the patient's clinical condition. Careful control of replacement therapy is especially important in cases of major surgery or life-threatening hemorrhages.

Inhibitors

Patients should be monitored for the development of factor IX inhibitors. If the expected factor IX activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a factor IX inhibitor is present.

In patients with high levels of inhibitor, factor IX therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of patients with hemophilia (See Warnings and Precautions).

In patients with inhibitor titers refractory to higher doses, the use of recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC) preparations should be considered.

Recommended Dose and Dosage Adjustment

I. Hemophilia B (4,5,6)

For the calculation of the factor IX plasma levels as specified below it is assumed that one IU of IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, per kg body weight increases the factor IX plasma level by approximately 0.8 %.

Considering the patient's pre-infusion factor IX plasma level, the required dosage is administered using the following formula:

$$\text{IMMUNINE VH dose (in IU F IX)} = \text{body weight (in kg)} \times \text{desired increase in F IX (in\%)} \times 1.21\text{U/kg}$$

Regular determinations of the patient's factor IX plasma level are necessary for monitoring the course of therapy and calculation of appropriate maintenance doses.

1. Hemorrhages and Surgery

The following table indicates which factor IX plasma levels are necessary for the

management of hemorrhages or for surgical prophylaxis and how long these levels need to be maintained:

Types of hemorrhage or surgical intervention	Therapeutically necessary F IX plasma level (% of normal)	Period during which it is necessary to maintain this F IX plasma level
Minor, e.g.: hemorrhages into joints	30%	At least 1 day, depending on the severity of the hemorrhage
Major, e.g.: hemorrhages into muscles, hemorrhages into the oral cavity, mild trauma capitis, tooth extractions, surgical interventions with low risk of hemorrhage	30 – 50%	3 -4 days, or until absorption of tissue hemorrhage or adequate wound healing
Life-threatening, e.g.: gastro-intestinal, intracranial, intraabdominal, or intrathoracic hemorrhages, fractions, major surgical interventions with high risk of hemorrhage	50 – 70%	After 7 days factor IX levels may be lowered, but therapy should be continued for at least another 7 days or until absorption of hemorrhage or adequate wound healing

In general, IMMUNINE VH is given every 24 hours, corresponding to the biological half-life of factor IX. For surgical prophylaxis the initial dose should be administered one hour prior to surgery. In the case of major surgical interventions, 12 hour treatment intervals should be maintained during the first post-operative days.

2. Prophylactic maintenance therapy (7)

In prophylactic maintenance therapy of severe hemophilia B, a dosage of 20 -30 IU/kg body weight twice per week was shown to be effective.

Prophylactic dosage regimens should, however, be tailored to individual needs, and the decision on the need and dosage for prophylaxis should thus be made by the treating physician.

II. Hemophiliacs with inhibitor to factor IX

Replacement therapy with human blood coagulation factor IX is usually effective only in low responder patients with an inhibitor titer of less than 10 Bethesda Units. Since the response to human blood coagulation factor IX depends on the patient's inhibitor titer, factor IX levels must be monitored frequently and the dose adjusted accordingly.

In high responder inhibitor patients other therapeutic measures may be needed.

Reconstitution

IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, is to be reconstituted only immediately before application. The solution should then be used promptly (the preparation does not contain any preservative). Any unused solution must be discarded. For reconstitution proceed as follows using aseptic technique:

1. Warm the unopened bottle containing Sterile Water for Injection (diluent) to room temperature (not above 37°C [98°F]).
2. Remove caps from the concentrate and diluent bottles to expose central portions of the rubber stoppers. Cleanse exposed surface of the rubber stoppers with germicidal solution and allow to dry.
3. Remove protective covering from one end of the transfer needle by twisting and pulling. Insert the exposed end through the diluent bottle stopper.
4. Remove protective covering from the other end of the transfer needle taking care not to touch the exposed end. Invert diluent bottle over the concentrate bottle and insert the free end of the transfer needle through the concentrate bottle stopper. Diluent will be drawn into the concentrate bottle by vacuum.
5. Disconnect the two bottles by removing the needle from the concentrate bottle stopper. Gently agitate or rotate the concentrate bottle until all material is dissolved.

Do not refrigerate after reconstitution.

Administration

The product should be administered via the intravenous route.

It is recommended not to administer at a rate exceeding 2 mL per minute.

It is strongly recommended that every time that IMMUNINE is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

For intravenous injection:

1. After reconstituting the concentrate as described under "Reconstitution", attach the enclosed filter needle to a sterile disposable syringe. Insert filter needle through the concentrate bottle stopper.
2. Inject air and withdraw solution into the syringe.
3. Remove and discard the filter needle. Attach a suitable intravenous needle or winged infusion set and inject solution intravenously (maximum rate 2 mL/min).

For intravenous infusion:

1. After reconstituting the concentrate as described under "Reconstitution", attach the enclosed filter needle to a sterile disposable syringe. Insert filter needle through the concentrate bottle stopper.
2. Inject air and withdraw solution into the syringe.
3. Remove and discard the filter needle. Attach a suitable intravenous needle or winged infusion set and inject solution intravenously (maximum rate 2 mL/min).

Infusion:

If administered by infusion, a disposable infusion set with adequate filter is to be used (maximum rate of infusion: 2 mL/min).

OVERDOSAGE

Based on experience with conventional prothrombin complex preparations, overdosage of Factor IX concentrates may result in an increased risk of myocardial infarction, disseminated intravascular coagulation, venous thrombosis and pulmonary embolism (see "PRECAUTIONS" for measures to be taken).

No symptoms of overdosage with purified FIX have been identified in humans. Therefore, the effects of higher than recommended doses of IMMUNINE have not been characterized.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Coagulation factor IX is one of the clotting factors found in normal human blood and is required for normal clot formation. Intravenous administration of IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO provides an increase in plasma levels of factor IX and can temporarily correct the coagulation defect of patients with factor IX deficiency.

The *in vivo* recovery and half-life of IMMUNINE VH were evaluated in 26 patients with severe hemophilia B (factor IX levels below 1 %) and no bleeding at the time of testing. The patients received a single infusion of 50-70 units IMMUNINE VH per kg body weight. The mean increase in the patients' factor IX plasma levels was 0.92 percent per administered IU factor IX per kg body weight, corresponding to a recovery of 41%. The average biological half-life was approximately 17 hours. These data are based on calculations using the new International Standard for Human Blood Coagulation Factors II, IX and X in Concentrates Code 84/681 (1).

Pharmacodynamics

See Part II of this Product Monograph

Pharmacokinetics

See Part II of this Product Monograph

STORAGE AND STABILITY

When stored between +2°C and +8°C (+35°F and +46°F), IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO is stable until the date indicated on the label.

Within the indicated shelf life IMMUNINE VH may temporarily be stored at room temperature [up to +25°C (+77°F)] for a period of up to 3 months. Record the period of storage at room temperature below the expiration date indicated on the package label. Discard product if stored at room temperature for three months.

IMMUNINE VH must not be used beyond the expiration date indicated on each pack.

Reconstituted Solutions

The reconstituted solution should be used immediately after preparation (contains no preservative), it should not be refrigerated and any unused portion of it should be discarded (See Dosing and Administration).

SPECIAL HANDLING INSTRUCTIONS

IMMUNINE is to be reconstituted only immediately before administration. The solution should then be used promptly (preparation does not contain any preservatives).

Reconstituted products should be inspected visually prior to administration. The solution should be clear or slightly opalescent. Do not administer if particulate matter or discoloration or cloudiness is found; contact Shire Customer Service.

DOSAGE FORMS, COMPOSITION AND PACKAGING

IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, is supplied in a single dose vial accompanied by a vial of Sterile Water for Injection, U.S.P. for diluent, a sterile transfer needle and a sterile filter needle as follows:

IMMUNINE VH	Sterile Water for Injection. USP
(IU ¹)	(mL)
480 to 720	5

The number of I. U.¹ Factor IX is stated on the label of each vial.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Factor IX Concentrate (Human), Vapor Heated, Immuno

Chemical Name: Not applicable

Molecular formula, molecular mass:

Human blood coagulation factor IX (Factor IX), is a single chain glycoprotein consisting of 415 amino acids with relative molecular mass of 57,000 Da.

Structural formula:

Factor IX contains 12-gamma-carboxylated glutamic acid residues, two epidermal growth factor regions, one activation peptide domain, and a serine protease region.

Physicochemical properties:

Factor IX is the zymogen from the serine protease Factor IXa. After activation and removal of the activation peptide, Factor IXa is a disulfide-linked two-chain serine protease specific for an arginine–isoleucine bond. Factor IXa and Factor VIIIa form a high-affinity complex on the phospholipid surface in the presence of calcium to activate Factor X by cleaving a single peptide bond in the aminoterminal region of the heavy chain.

Product Characteristics

IMMUNINE VH is a highly purified factor IX concentrate containing only traces of other coagulation factors (up to 0.02 IU of factors II, VII and X per IU factor IX). In preclinical trials utilizing supra-therapeutic doses of IMMUNINE VH no thrombotic adverse reactions were observed. IMMUNINE VH is prepared from pooled human plasma.

IMMUNINE VH contains less than 0.1 IU heparin per ml and not more than 5µg TWEEN 80 per ml.

The manufacturing process includes key stages, among them a product-specific vapor heat treatment (8), that have been shown to result in removal and inactivation of infectious agents.

Individual donations of human plasma are combined to form plasma pools. Prior to being used for manufacture of IMMUNINE VH, each plasma pool is tested for the presence of genome sequences of the human immunodeficiency virus type 1, hepatitis B virus (HBV), and hepatitis C virus (HCV) using IQ-PCR^b.

To prevent the transmission of infective agents by the administration of IMMUNINE VH, prescribed procedures are used for the collection and testing of the source plasma and during the manufacture of the product. They include measures taken for donor and plasma selection^c, as well as virus removal and inactivation steps during manufacturing.

Viral Inactivation

A virus panel representing a wide range of physicochemical characteristics was used in virus clearance studies investigating the virus reduction capacity of the IMMUNINE VH production process. Whenever feasible relevant target viruses, i.e. viruses, which could potentially be present in human plasma, were used in the virus clearance studies:

Human Immunodeficiency virus type I (HIV-1) and Hepatitis A Virus (HAV) were used as target viruses.

For viruses which cannot be titrated in established cell lines, e.g. HCV and Parvovirus B19, model viruses were used:

Pseudorabies virus (PRV, an enveloped DNA virus as a generic model for hepatitis B virus), Bovine Viral Diarrhea Virus (BVDV, a small enveloped RNA virus as a model for HCV) and Mice Minute Virus (MMV, small, non-enveloped DNA virus as model virus for Parvovirus B19 and other small, non-enveloped DNA viruses).

A summary table of the virus validation studies performed is given below. Intermediates of IMMUNINE were obtained from the manufacturing facility. Aliquots of the intermediate were spiked with viruses and the virus inactivation/removal capacity of the respective process step was investigated. Mean reduction factors are listed in the table below. Where two or more reduction factors are available for a specific manufacturing step, the mean value was used to calculate the ORF.

^b IQ-PCR: IMMUNO Quality Assured Polymerase Chain Reaction

With this method 500 genome equivalents/ml of the above viruses can be determined reliably, with the actual sensitivity of IQ-PCR being below that. Therefore all pools which have been tested and evaluated as being sensitive lead to exclusion from further processing. No correlation has been demonstrated between infectivity and removal of pools containing these levels of genomic equivalents from further manufacturing.

^c All plasma units used for manufacture are ALT tested and non-reactive in tests for HBs-antigen and antibodies to HCV, HIV-1 and HIV-2. Before further processing all individual plasma donations are subjected to an inventory hold of at least three months for a possible look-back of plasma donations suspected of infection.

Virus Validation Studies- Summary Table

Intermediate (Step)	Log ₁₀ Reduction Factor					
	HIV-1	HAV	PRV	BVDV	MMV ^d	B19V
Purification of Factor IX complex from cryosupernatant with DEAE-Sephadex	n.d.	1.4	n.d.	n.d.	1.3	3.6 (PCR)
Polysorbate 80 treatment followed by Ion Exchange Chromatography ^e	>5.1	2.8	3.4	>4.7	1.2	n.d.
Freeze Drying & Vapor Treatment	>6.6	>4.2	>7.6	>6.6	1.3	n.d.
Overall Log₁₀ Reduction Factor (ORF)	>11.7	>8.4	>11.0	>11.3	3.8	3.6

n.d. not determined

In prospective clinical studies as well as in post-marketing surveys, the risk of transfusion-transmitted viral infections was followed up in patients given factor concentrates of the prothrombin complex subjected to the same vapor heat treatment as IMMUNINE VH. Using the criteria established by the ISTH, 45 patients were evaluated for non-A/non-B transmission and 27 for hepatitis B transmission. In addition, 42 patients were evaluated for HCV seroconversion, and 105 for HIV seroconversion. No cases of product related viral hepatitis or HIV transmission were observed (9).

DETAILED PHARMACOLOGY

Animals

Pharmacodynamic studies related to the proposed indication or pharmacokinetic studies were not performed. The reason for this is that no animal model of Factor IX deficiency is available and that - because of species-specificity of the coagulation factors - data obtained in animals cannot

^d MMV is however, not an appropriate B19V model for heat treatment steps as MMV is substantially more heat resistant than B19V, as also evident by the two publications cited below:

- M. Yunoki *et al.*, Heat sensitivity of human parvovirus B19, *Vox Sanguinis* (2003) 84, 164-169
- Blümel *et al.*, Inactivation of parvovirus B19 during pasteurization of human albumin, *Transfusion* (2002), 42, 1011-1018

^e For HIV-1 and BVDV, the reduction factors apply to the P80 treatment only.

be extrapolated to humans. For general pharmacodynamic studies see "Animal Toxicology" below.

Humans

Pharmacodynamics

Normalization of the coagulation defect in factor IX deficient patients has been investigated in an international study determining the efficacy of IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, in the control of bleeding and perioperative bleeding prophylaxis in hemophilia B patients. IMMUNINE VH was found effective in 322 evaluable treatment courses given to 57 patients (10).

Pharmacokinetics

In vivo recovery and half life characteristics were evaluated in an international, prospective, controlled, cross-over study following ISTH guidelines. A total of 26 patients with an age of more than 12 years with severe hemophilia B (factor IX level < 1 %), and not bleeding at the time of testing, have been given a single infusion of 50-70 IU/kg body weight at 10 day intervals of either IMMUNINE VH or BEBULIN VH, IMMUNO's Factor IX Complex licensed in Canada since 1988. Mean half life observed was 17.42 h for IMMUNINE VH vs. 18.77 h for BEBULIN VH whereas mean *in vivo* recovery was 0.92 percent per administered IU factor IX per kg bodyweight for IMMUNINE VH vs. 1.02 percent for BEBULIN VH.

TOXICOLOGY

Humans

In the international trial described under Pharmacokinetics on the previous page also tolerance in humans was evaluated. Recipients of IMMUNINE VH, Factor IX Concentrate (Human) Vapor Heated, IMMUNO, were followed up regularly for any signs of adverse reactions such as rigor, nausea, headache, dizziness, drop in blood pressure or tachycardia. IMMUNINE VH was very well tolerated in the receiver patients.

Animals

In the test for acute toxicity following intravenous application in mice and rats it was shown that the maximum dose which did not cause death of the animals was 21 (mice) and 16.7 times (rats) higher than the maximum dose recommended in humans.

Studies on subacute and chronic toxicity as well as studies on reproduction toxicity and mutagenic or tumorigenic potential were not performed since repeated administration of Factor IX would be liable to cause the formation of antibodies in the animals. Results obtained in the animal model would hence not allow extrapolation to humans.

When tested in rabbits using the Wessler method of assessing thrombogenicity IMMUNINE VH failed to show any evidence of thrombogenicity even at a dose of 1000 IU/kg.

When IMMUNINE VH was administered intra-arterially to guinea pigs at a dose of 200 IU/kg no anaphylactoid effects were noted.

Following administration of IMMUNINE VH in an anesthetized dog model (200 IU/kg i.v.) no changes in blood pressure, heart rate or ECG were observed.

Data on the efficacy of the vapor heat treatment on viral safety of the preparation have been previously described in the chapter on 'Clinical Pharmacology'.

REFERENCES

1. BARROWCLIFFE T. W.: Standardization of Factors II, VII, IX and X in Plasma and Concentrates. Report of the ICTH Subcommittee on Factors VIII and IX, Brussels, July 1987. *Thrombosis and Haemostasis* 59(2) 334 (1988).
2. WHO: Human blood coagulation factors II, IX and X in concentrates. WHO Technical Report Series 771, 23-24 (1988)
3. SCHARRER I.: *Acta Haematologica* 95, Vol. 94, Suppl. 1,2-7
4. LEVINE P.H.: The Clinical Manifestations and Therapy of Hemophilias A and B. In: R. W. Colman, J. Hirsh, V.J. Marder, E. W. Salzman (Eds.): *Hemostasis and Thrombosis*. J.B. Lippincott Company, Philadelphia, 97-111 (1987)
5. EC-Note for Guidance "Core Summary of Product Characteristics for HUMAN PLASMA COAGULATION FACTOR IX CONCENTRATE, III/3458/92-EN
6. ABE T., KAZAMA M.: An International Survey on the Appropriate Dosage of Hemophilias and Related Congenital Coagulopathies. *Proceedings of the 3rd International Symposium on Haemostasis and Thrombosis: 273-304 (1982)*
7. SCHIMPF K., BAUMANN P.: Die ambulante Dauerbehandlung der Hämophilie B. *Dtsch. med. Wschr.* 101: 233-238 (1976)

8. ELSINGER F., WÖBER G., DORNER F., EIBL J., LINNAU Y., PHILAPITSCH A., SCHWARZ A.: Steam Treatment of Freeze-Dried Plasma Fractions. In: N .L. Ciavarella. Z.M. Ruggeri, Th.S. Zimmermann (Eds.): Factor VIII von Willebrand Factor -Biological and Clinical Advances. Wichtig Editore srl. Milano, 297-302 (1986)
9. Data on file at the IMMUNO corporation, Vienna
10. Data on file at Österreichisches Institut für Haemoderivate Ges.m.b.H., Vienna.
11. KASPER C.K., RICKARD K, ALEDORT L.M.: Minutes of Amsterdam Meeting, 29 June 1991, of the Subcommittee on Factors VIII & IX. Unpublished

PART III: CONSUMER INFORMATION

IMMUNINE VH (Factor IX Concentrate (Human), Vapor Heated, IMMUNO)

This leaflet is part III of a three-part "Product Monograph" published when IMMUNINE VH was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about IMMUNINE VH. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

IMMUNINE VH is a Factor IX protein used for therapeutic and prophylactic (preventative) use in patients suffering from congenital (haemophilia B) or acquired factor IX deficiency.

What it does:

IMMUNINE VH is administered by intravenous (IV) therapy and provides an increase in plasma levels of factor IX. IMMUNINE VH can temporarily correct the coagulation defect of patients with factor IX deficiency and therefore stop the bleeding episodes.

When it should not be used:

IMMUNINE VH should not be used if:

- You suffer from DIC and/or hyperfibrinolysis; or
- You have a known allergy to heparin or history of heparin induced thrombocytopenia; or
- If you experience hypersensitive reactions occurs during administration of IMMUNINE VH; or
- You are pregnant or nursing mothers (only use if clearly needed); or
- You have had a recent myocardial infarction, stroke or thromboembolic events.

What the medicinal ingredient is:

IMMUNINE VH contains freeze dried Factor IX concentrate of high purity containing traces of Factors II, VII and X (<0.02 IU / 1 IU factor IX).

What the important nonmedicinal ingredients are:

Factor II, VII and X (<0.02 IU / 1 IU factor IX), Tween 80, Sodium Chloride, Sodium Citrate and Sterile Water for Injection.

For a full listing of nonmedicinal ingredients see Part I of the product monograph.

What dosage forms it comes in:

IMMUNINE VH is a sterile freeze dried powder and supplied in a single dose vial accompanied by a vial of Sterile Water for Injection, EP as diluent, a sterile transfer needle, and a sterile filter needle. It is available in the following package sizes:

IMMUNINE VH (IU)	Sterile Water for Injection EP (mL)
480 to 720	5

The number of IU Factor IX is stated on the label of each vial.

WARNINGS AND PRECAUTIONS

Because IMMUNINE VH is made from human plasma, a risk of transmitting infectious agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The use of IMMUNINE VH may lead to hypersensitivity reactions. Hypersensitivity reactions refer to undesirable reactions produced by the normal immune systems such as allergies. At first signs or symptoms of hypersensitivity reactions, IMMUNINE VH treatment should be stopped and medical care should be started as appropriate.

Your body may form inhibitors to factor IX. An inhibitor is an antibody (part of your body's normal immune defenses) that forms in response to infusions of factor IX that prevents the factor IX from working properly. These inhibitors can lead to a reduced response or to no response to factor IX therapy. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors.

The use of factor IX may lead to the development of blood clots in your veins. This is particularly dangerous if you have disseminated intravascular coagulation (DIC) or fibrinolysis. If you have DIC or are at risk of DIC, please discuss with your doctor whether the use of IMMUNINE VH is right for you.

BEFORE you use IMMUNINE VH talk to your doctor or pharmacist if:

- You have known allergies to this drug, to heparin, or to any ingredient in the formulation or component of the product
- You have thromboembolism, DIC, or fibrinolysis
- You are pregnant or may be pregnant
- You are a nursing mother

INTERACTIONS WITH THIS MEDICATION

No interactions with other drugs are currently known. IMMUNINE VH should not be mixed with other drugs.

PROPER USE OF THIS MEDICATION

Usual dose:

The dose of the treatment depends on the severity of factor IX deficiency, the location and extent of the bleeding, and the patient's clinical condition. The treatment should be carried out by a doctor who is familiar with the treatment of haemophilia.

Overdose:

Overdosage may increase your risk of myocardial infarction, DIC, venous thrombosis, and pulmonary embolism.

IMMUNINE VH, should not be administered at a rate exceeding 2 mL/min.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

Not applicable.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

- Although rare, severe allergic reactions may occur.
- If you develop fever, skin rashes, nausea, retching, shortness of breath, a drop in blood pressure or shock you should stop the use of IMMUNINE VH and contact your doctor or visit the Emergency Department immediately.
- Mild allergic reactions may be managed with antihistamine.

The following side effects have been reported:

- Allergic reaction
- Headache
- Myocardial Infarction, Tychycardia
- Flushing
- Shortness of Breath
- Skin rashes
- Chills

This is not a complete list of side effects. For any unexpected effects while taking IMMUNINE VH, contact your doctor or pharmacist.

HOW TO STORE IT

IMMUNINE VH should be stored in the refrigerator at a temperature between 2°C and 8°C.

IMMUNINE VH may be temporarily stored at room temperature (up to +25°C) for a period of up to 3 months. Record the period of storage at room temperature below the expiration date indicated on the package label. Dispose of the product if stored at room temperature for three months or longer.

IMMUNINE VH must not be used beyond the expiration date indicated on each pack.

The reconstituted solution contains no preservatives and should be used immediately after preparation. Dispose of any unused portion. Do not refrigerate any unused portion.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:

toll-free telephone: 866-234-2345
toll-free fax: 866-678-6789
By email: cadtmp@hc-sc.gc.ca

By regular mail:
National AR Centre
Marketed Health Products Safety and Effectiveness
Information Division
Marketed Health Products Directorate
Tunney's Pasture, AL 1908C
Ottawa ON K1A 0K9

NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:
www.shirecanada.com or by contacting the sponsor, Shire Pharma Canada ULC at: 1-800-268-2772.

This leaflet was prepared by:

Shire Pharma Canada ULC
22 Adelaide Street West, Suite 3800
Toronto Ontario M5H 4E3

Last revised: April 23, 2018